
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59B0AB925F53A33AB0AB0037519FAB.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="nat">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Nucleic Acid Therapeutics">
<meta name="citation_title" content="Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis">
<meta name="citation_author" content="Rosie Z Yu">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_author" content="Jon W Collins">
<meta name="citation_author_institution" content="GlaxoSmithKline, Research Triangle Park, North Carolina, USA.">
<meta name="citation_author" content="Shannon Hall">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_author" content="Elizabeth J Ackermann">
<meta name="citation_author_institution" content="Otonomy, Inc., San Diego, California, USA.">
<meta name="citation_author" content="Richard S Geary">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_author" content="Brett P Monia">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_author" content="Scott P Henry">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_author" content="Yanfeng Wang">
<meta name="citation_author_institution" content="Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.">
<meta name="citation_publication_date" content="2020 May 22">
<meta name="citation_volume" content="30">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="153">
<meta name="citation_doi" content="10.1089/nat.2019.0822">
<meta name="citation_pmid" content="32286934">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/pdf/nat.2019.0822.pdf">
<meta name="description" content="A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure–response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis ...">
<meta name="og:title" content="Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure–response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="7249474">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1089/nat.2019.0822"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/nat.2019.0822.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC7249474%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/7249474/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/7249474/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nat.png" alt="Nucleic Acid Therapeutics logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Nucleic Acid Therapeutics" title="Link to Nucleic Acid Therapeutics" shape="default" href="https://doi.org/10.1089/nat.2019.0822" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Nucleic Acid Ther</button></div>. 2020 May 22;30(3):153–163. doi: <a href="https://doi.org/10.1089/nat.2019.0822" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1089/nat.2019.0822</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Nucleic%20Acid%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nucleic%20Acid%20Ther%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Nucleic%20Acid%20Ther%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Nucleic%20Acid%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20RZ%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Rosie Z Yu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Rosie Z Yu</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20RZ%22%5BAuthor%5D" class="usa-link"><span class="name western">Rosie Z Yu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collins%20JW%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Jon W Collins</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Jon W Collins</span></h3>
<div class="p">
<sup><sup>2</sup></sup>GlaxoSmithKline, Research Triangle Park, North Carolina, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collins%20JW%22%5BAuthor%5D" class="usa-link"><span class="name western">Jon W Collins</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hall%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Shannon Hall</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Shannon Hall</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hall%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shannon Hall</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ackermann%20EJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Elizabeth J Ackermann</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Elizabeth J Ackermann</span></h3>
<div class="p">
<sup><sup>3</sup></sup>Otonomy, Inc., San Diego, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ackermann%20EJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Elizabeth J Ackermann</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Geary%20RS%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Richard S Geary</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Richard S Geary</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Geary%20RS%22%5BAuthor%5D" class="usa-link"><span class="name western">Richard S Geary</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Monia%20BP%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Brett P Monia</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Brett P Monia</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Monia%20BP%22%5BAuthor%5D" class="usa-link"><span class="name western">Brett P Monia</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Henry%20SP%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Scott P Henry</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Scott P Henry</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Henry%20SP%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott P Henry</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Yanfeng Wang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Yanfeng Wang</span></h3>
<div class="p">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yanfeng Wang</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup><sup>1</sup></sup>Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.</div>
<div id="aff2">
<sup><sup>2</sup></sup>GlaxoSmithKline, Research Triangle Park, North Carolina, USA.</div>
<div id="aff3">
<sup><sup>3</sup></sup>Otonomy, Inc., San Diego, California, USA.</div>
<div class="author-notes p"><div class="fn" id="corr1">
<sup>✉</sup><p class="display-inline">Address correspondence to: Rosie Z. Yu, PhD, Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA <span>ryu@ionisph.com</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2019 Sep 3; Accepted 2020 Jan 13; Issue date 2020 Jun 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Rosie Z. Yu et al. 2020; Published by Mary Ann Liebert, Inc.</div>
<p>This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<a href="http://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC7249474  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32286934/" class="usa-link">32286934</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>A population pharmacokinetic (PK) and pharmacodynamic (PD) model was developed for inotersen to evaluate exposure–response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (TTR) amyloidosis polyneuropathy (hATTR-PN). Inotersen PK and TTR level (PD) data were composed of one Phase 1 study in healthy subjects, one Phase 2/3 study in hATTR patients, and its one open-label extension study. Effects of intrinsic and extrinsic factors (covariates) on PK and PK/PD of inotersen were evaluated using a full model approach. Inotersen PK was characterized by a two-compartment model with elimination from the central compartment. The population PK analysis identified disease status and lean body mass (LBM) as significant covariates for inotersen PK. Nonetheless, the contribution of disease status and LBM on PK was small, as the difference in clearance (CL/<em>F</em>) was 11.1% between healthy subjects and patients with hATTR-PN and 38% between the lowest and highest LBM quartiles of the patient population. Age, race, sex, baseline renal function estimated glomerular filtration rate, and hepatic function markers (baseline albumin, bilirubin, and alanine aminotransferase values) were not statistically significant covariates affecting inotersen PK. An inhibitory effect indirect-response model (inhibition of TTR production) was used to describe the drug effect on TTR-time profiles, with baseline TTR included as a covariate. The overall population <em>I</em><sub>max</sub> and IC<sub>50</sub>, together with 95% confidence interval, was estimated to be 0.913 (0.899–0.925) and 9.07 (8.08–10.1) ng/mL, respectively. V30M mutation showed no effect on the estimated IC<sub>50</sub> value for hATTR patients. The final population PK and PK/PD model was used to simulate four different treatment regimens. The population PK/PD model developed well described the PK and PD of inotersen in patients with hATTR-PN and has been used for label recommendation and trial simulations.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> pharmacokinetics, pharmacodynamics, antisense, oligonucleotide, inotersen, hereditary TTR amyloidosis</p></section></section><section id="s001"><h2 class="pmc_sec_title">Introduction</h2>
<p>Hereditary transthyretin amyloidosis (hATTR) is a rare and fatal disease caused by mutations in the gene that codes for transthyretin (TTR) [<a href="#B1" class="usa-link" aria-describedby="B1">1</a>]. Single-point gene mutations destabilize the normal tetrameric structure of TTR protein causing its dissociation into free monomers and subsequent aggregation into insoluble extracellular deposits [<a href="#B2" class="usa-link" aria-describedby="B2">2</a>,<a href="#B3" class="usa-link" aria-describedby="B3">3</a>]. These deposits accumulate in multiple organs (including the peripheral nervous system, gastrointestinal tract, kidney, and heart) resulting in severe damage to cells, which causes the development of motor and sensory neuropathy, autonomic neuropathy, nephropathy, and cardiomyopathy [<a href="#B4" class="usa-link" aria-describedby="B4">4</a>]. On average, death occurs within ∼10 years from symptom onset (but is shorter when significant cardiomyopathy is present) and is primarily due to malnutrition and cachexia, renal failure, and cardiac disease [<a href="#B4" class="usa-link" aria-describedby="B4">4</a>]. The only treatment option for hATTR was liver transplant, until the approval of two treatment options in 2018: patisiran (Onpattro<sup>®</sup>; Alnylam Pharmaceuticals) and inotersen (Tegsedi<sup>TM</sup>; Ionis Pharmaceuticals and Akcea Therapeutics), and both markedly changed the treatment landscape for this debilitating disease. Inotersen (also known as ISIS 420915) was approved by the European Commission, Canada, the U.S. Food and Drug Administration, and Brazil for the treatment of stage 1 or stage 2 polyneuropathy (PN) in adult patients with hATTR.</p>
<p>The strategy of treating hATTR patients with inotersen is to reduce the levels of mutated and wild-type TTR protein secreted by the liver, a primary organ for antisense oligonucleotide (ASO) distribution following systemic administrations. Inotersen is a 2′-<em>O</em>-(2-methoxyethyl) (2′-MOE) modified phosphorothioate oligonucleotide, which targets to the messenger RNA (mRNA) of human TTR via Watson–Crick base pairing and prevents expression of the encoded “disease-related” TTR protein. Inotersen demonstrated potent activity <em>in vitro</em> in reducing TTR mRNA levels in HepG2 cells and primary hepatocytes. Pharmacology studies conducted with inotersen in human TTR transgenic mice and cynomolgus monkeys demonstrated reproducible and robust reductions in liver TTR mRNA levels, which were accompanied by equally robust and significant reductions in plasma TTR protein levels.</p>
<p>The clinical experience included a Phase 1 double-blind, placebo-controlled, dose-escalation, first-in-human clinical study and a Phase 2/3 pivotal study in hATTR patients with open-label extension (OLE) up to 5 years. In the Phase 1 study, dose- and exposure-dependent reductions in plasma TTR levels were observed with an acceptable safety and tolerability profile when administered subcutaneously (SC) to healthy subjects up to 400 mg inotersen per week for 4 weeks. An exploratory pharmacokinetic (PK)/pharmacodynamic (PD) model was developed based on Phase 1 data [<a href="#B5" class="usa-link" aria-describedby="B5">5</a>] and was used to simulate TTR reduction at various dosing regimens. PK/PD simulations predicted that over 80% or 90% of patients would achieve TTR reduction of &gt;60% or &gt;50%, respectively, following 3 months of 300 mg inotersen once per week (QW). Therefore, the 300 mg once weekly dosing regimen was selected for the pivotal Phase 2/3 study. In the Phase 2/3 study in hATTR-PN patients, a 68%–74% mean (median: 75%–79%) reduction in TTR levels was achieved from week 13 to 65 of treatment with 300 mg inotersen QW and maintained throughout the 15-month treatment period in inotersen-treated subjects, consistent with results obtained in the inotersen Phase 1 healthy volunteer study [<a href="#B6" class="usa-link" aria-describedby="B6">6</a>]. The robust and persistent TTR reductions in hATTR patients were accompanied by clinically and statistically significant benefit in favor of inotersen treatment, as demonstrated by both primary end points [modified Neuropathy Impairment Score (mNIS) +7 and Norfolk Quality of Life Diabetic Neuropathy (QoL-DN)], as well as multiple prespecified sensitivity analyses, in multiple secondary, tertiary, and exploratory end points. Therefore, these results demonstrated that inotersen treatment provides clinical benefit to multiple aspects of the disease, including muscle weakness, large and small fiber sensation, and trends for benefit for autonomic symptoms. The overall safety profiles following chronic inotersen treatment were manageable. Taken together, these findings support the use of inotersen for the treatment of patients with hATTR.</p>
<p>The clinical PKs and PDs of inotersen have been evaluated in the first-in-human Phase 1 clinical study and the Phase 2/3 pivotal study with OLE by measuring plasma drug levels and serum TTR levels over time. The objective of this work was to develop a population PK and PK/PD model that describe the PKs and PDs of inotersen following SC administrations and evaluate the effect of intrinsic and extrinsic factors that potentially affect PK and PK/PD of inotersen and to perform alternative dose regimen simulations using the established PK/PD model.</p></section><section id="s002"><h2 class="pmc_sec_title">Materials and Methods</h2>
<section id="s003"><h3 class="pmc_sec_title">Test compounds</h3>
<p>Inotersen is a synthetic ASO of 20 nucleotides (ie, a 20-mer) in length that are connected sequentially by phosphorothioate linkages, with a total of ten 2′-MOE modified ribofuranosyl nucleotides. The sequence of inotersen is: <span class="text-underline">T<sup>M</sup>CTTG</span> GTTA<sup>M</sup>CATGAA <span class="text-underline">AT<sup>M</sup>C<sup>M</sup>C<sup>M</sup>C</span> with 2′-MOE modifications at positions 1–5 and 15–20 (underlined). In addition, all the cytosines of the compound were modified to contain a 5-methyl group (5-methyl cytosine, <sup>M</sup>C). The molecular formula of inotersen is C<sub>230</sub>H<sub>299</sub>N<sub>69</sub>O<sub>121</sub>P<sub>19</sub>S<sub>19</sub> Na<sub>19</sub>, and the molecular weight is 7600.8 amu. The molecular target of inotersen is within the 3′ untranslated region of the human TTR mRNA and binds to the mRNA using Watson and Crick base pairing.</p>
<p>Inotersen was formulated in water-for-injection (200 mg/mL) and supplied as a sterile solution in a 1 or 1.5 mL deliverable volume in a sealed glass vial or as a single-dose prefilled syringe in a 1.5 mL deliverable volume and contains no preservatives.</p></section><section id="s004"><h3 class="pmc_sec_title">Clinical studies</h3>
<p>All studies were performed according to the amended Declaration of Helsinki, and all patients provided written informed consent.</p>
<p>All three clinical studies conducted with inotersen by Ionis Pharmaceuticals were included in this population PK and PK/PD analysis.</p>
<p>The first study was a Phase 1 double-blind, placebo-controlled, dose-escalation study designed to assess the safety, tolerability, PKs, and PDs of single and multiple doses of inotersen administered SC to healthy subjects. Four single-dose cohorts (50, 100, 200, and 400 mg) and five multiple-dose cohorts (50, 100, 200, 400, and 300 mg) were evaluated sequentially with 3:1 or 8:2 randomization to inotersen or placebo, respectively. Subjects enrolled in the multiple-dose cohorts received a total of six doses of Study Drug (inotersen or placebo) administered by SC injection: three doses on alternate days during the first week (days 1, 3, and 5) and then once a week for the next 3 weeks (days 8, 15, and 22). All doses were administered as single SC injections with the exception of the 400 mg doses, which were administered as two 200 mg SC injections. The study enrolled 65 healthy volunteers (16 in the single-dose cohorts and 49 in the multiple-dose cohorts). Of the 65 subjects, 51 were administered inotersen and 14 were administered placebo.</p>
<p>Plasma samples for measurement of inotersen concentrations were collected at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h following the SC injection on day 1 for the single-dose cohorts and on days 1 and 22 for the multiple-dose cohorts. Plasma trough samples were collected before dose on days 3, 5, 8, 15, and 22 in the multiple-dose cohorts. In addition, post-treatment plasma samples for determination of elimination half-life were collected during the post-treatment follow-up period, on days 4 and 8 in the single-dose cohorts and on days 29, 36, 50, 64, 78, and 92 in the multiple-dose cohorts. Serum samples for TTR analysis (PD) was collected at screening, predose, 24 h postdose, and on days 4 and 8 in the single-dose cohorts and at predose and 24 h postdose on days 1, 3, 5, 8, 15, and 22 and during post-treatment period on days 29, 36, 43, 50, 64, 78, and 92 in the multiple-dose cohorts.</p>
<p>The second study was a pivotal Phase 2/3 randomized, double-blind placebo-controlled study to assess the efficacy and safety of inotersen in patients with hATTR. The primary objective was to evaluate the efficacy of inotersen compared to placebo, given for 65 weeks, as measured by the change from baseline in the mNIS +7 and in the Norfolk QoL-DN questionnaire total score, in patients with hATTR. Patients were randomized in a 2:1 ratio to receive 300 mg inotersen or placebo. Study Drug (inotersen or placebo) was administered thrice on alternate days during week 1 (days 1, 3, and 5) and once weekly thereafter. A total of 172 subjects were dosed; 112 were administered inotersen and 60 received placebo. If required for safety or tolerability reasons, temporary dose reductions or interruptions were permitted. Plasma trough PK and PD samples were collected from all patients during the 65-week treatment phase and post-treatment follow-up period (if available). In addition, serial plasma samples were collected on days 1, 240, and 449 (weeks 1, 35, and 65, respectively) from a small number of subjects (a total of 10 subjects) at selected sites enrolled in the PK subgroup, for the assessment of inotersen PK in patients with hATTR.</p>
<p>The third study was an OLE study for eligible patients who had satisfactorily completed the pivotal Phase 2/3 as described above, and patients received 300 mg inotersen SC once weekly for up to 260 weeks (5 years) in the OLE study. Subjects who had a dose reduction or schedule change in the pivotal Phase 2/3 study were permitted to continue with the adjusted dose level or schedule in the OLE study. A total of 108 subjects had at least one evaluable PK sample and were included in the analysis. Plasma trough PK and PD samples were collected periodically from patients in the OLE study.</p>
<p>There were total of 202 subjects in the study dataset, with 74.8% (<em>N</em> = 151) of the analysis population being patients with hATTR and 25.2% (<em>N</em> = 51) being healthy subjects (<a href="#tb1" class="usa-link">Table 1</a>). Most individuals were Caucasian (87.6%), with 7.43% African Americans and 3.47% Asians. There were more males (69.8%) than females in the analysis population. There was no use of nonsteroidal anti-inflammatory drugs (NSAID), antirheumatic products, or renin-angiotensin agent in the hATTR population; however, roughly a third of the hATTR population used diuretics (30.5%) or antithrombotic agents (36.4%), and 83.4% of the hATTR patients used non-NSAID analgesic agents. Healthy volunteers from the Phase 1 study were younger on average, had slightly higher baseline TTR levels, and had lower total bilirubin levels than hATTR patients in the pivotal Phase 2/3 study.</p>
<section class="tw xbox font-sm" id="tb1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Summary of Subject Demographics and Baseline Laboratory Values</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="left" valign="bottom" colspan="1" rowspan="1">Parameter</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Mean (SD)</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Minimum</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Median</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Maximum</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Units</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">N<sub>Subjects</sub>
</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Age</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">55.4 (13.8)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">25.0</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">57.0</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">81.0</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Years</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Height</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">172 (9.43)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">144</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">173</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">196</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Cm</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Ideal body weight</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">66.2 (10.0)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">38.1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">68.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">89.2</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Kg</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Lean body mass</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">51.7 (8.44)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">31.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">51.6</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">80.3</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Kg</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Lean body weight</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">54.8 (10.0)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">31.4</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">54.9</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">82.9</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Kg</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Weight</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">72.7 (16.2)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">37.0</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">71.8</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">140</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Kg</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">BMI</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">24.6 (4.45)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">13.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">24.5</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">40.2</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">kg/m<sup>2</sup>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">BSA</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.85 (0.223)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.30</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.83</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">2.61</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">m<sup>2</sup>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">TTR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">22.0 (5.95)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.80</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">22.1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">39.7</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mg/dL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Albumin</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">4,249 (314)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3,167</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">4,233</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">5,000</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mg/dL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ALT</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">23.1 (10.8)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.00</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">83.2</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">U/L</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">AST</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">25.5 (7.68)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">12.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">24.0</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">60.0</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">U/L</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Total bilirubin</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.586 (0.306)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.0800</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.517</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">2.18</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mg/dL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">CrCL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">100 (34.0)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">35.2</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">97.9</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">220</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mL/min</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">eGFR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">93.2 (19.9)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">41.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">93.9</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">148</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mL/min/1.73 m<sup>2</sup>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">202</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tb1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tf1"><p><em>N</em><sub>Subjects</sub> refers to the number of subjects over which the parameter statistics were computed and included five subjects who received treatment but had no PK observations.</p></div>
<div class="fn" id="tf2"><p>PK, pharmacokinetic; BMI, body mass index; TTR, transthyretin; BSA, body surface area; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CrCL, creatinine clearance; eGFR, estimated glomerular filtration rate.</p></div>
</div></section></section><section id="s005"><h3 class="pmc_sec_title">Analytical methods</h3>
<section id="s006"><h4 class="pmc_sec_title">Quantitation of inotersen concentrations in plasma</h4>
<p>All plasma samples were analyzed using a quantitative, sensitive, hybridization-based enzyme-linked immunosorbent assay method, a variation on the method reported previously [<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. The assay was validated for precision, accuracy, selectivity, sensitivity, hook effect, metabolite cross-reactivity and interference, stability, and lack of antidrug antibody (ADA) interference in the quantitation of inotersen before analysis of the human plasma samples.</p>
<p>Plasma sample analyses were conducted at Covance Laboratories (West Trenton, NJ) and were performed based on the principles and requirements described in 21 CFR Part 58. The assay conducted with synthesized putative shortened oligonucleotide metabolite standards showed no measurable cross-reactivity, confirming the assay's specificity for inotersen. The quantitation range was 1.00–200 ng/mL, with the lower and higher ends of the range defining the lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ), respectively. There were no active metabolites for inotersen present in plasma.</p></section><section id="s007"><h4 class="pmc_sec_title">Quantitation of TTR in serum</h4>
<p>Serum samples for TTR (aka prealbumin) were analyzed by South Bend Medical Foundation (South Bend, IN) using a standardized immunoturbidimetric assay on Roche automated clinical chemistry analyzers. Anti-prealbumin antibodies reacted with the antigen in the sample to form antigen/antibody complexes, which were determined turbidimetrically after agglutination. The quantitation range of the assay was from 3 to 80 mg/dL (ie, 30–800 ng/mL), with the lower and higher ends of the range defining the LLOQ and ULOQ, respectively.</p></section></section><section id="s008"><h3 class="pmc_sec_title">Data analyses</h3>
<p>A population model using nonlinear mixed-effects modeling software, NONMEM<sup>®</sup> (version 7.2; ICON Plc, Hanover, MD), was developed to quantitatively characterize the PKs and PDs of inotersen to evaluate effects of covariates on inotersen PK/PD and to determine the inter- and intrasubject variability. A sequential modeling approach was used where a population-based PK model was established first to describe the kinetics of inotersen and, subsequently, using the <em>post hoc</em> PK as input to develop the population-based PD model. The first order conditional estimation method with interaction was used throughout model development.</p>
<p>Model features (eg, lag times, compartments, covariances, and so on) were added or removed based on evaluation of diagnostic plots, consideration of biological plausibility, and statistical tests. For hierarchical (or nested) models, the significance of adding or removing a parameter was assessed using the likelihood ratio test. For these models, the difference in the objective function value (ΔOFV) is ∼<em>χ</em><sup>2</sup> distributed with n degrees of freedom. As such, considering a significance level (α) of 0.05, the proposed change to the model was considered to improve the model fit only if ΔOFV is at least 3.84 when <em>n</em> = 1 and 5.99 for <em>n</em> = 2. In contrast, for non-nested models, the Akaike Information Criterion (AIC) and/or the Bayesian Information Criterion (BIC) were used to compare models following the principle that the lower the AIC and/or BIC, the better the model.</p></section><section id="s009"><h3 class="pmc_sec_title">Population PK modeling</h3>
<p>The population PK analysis included pooled data from three clinical studies in healthy volunteers and patients with hATTR-PN, as described above. The analysis dataset consisted of 202 subjects (51 healthy volunteers and 151 patients with hATTR-PN), among which 5 patients with hATTR-PN did not have PK data yet at the time of analysis. Therefore, available PK data from 197 subjects (51 healthy volunteers and 146 patients with hATTR-PN) with a total of 3,602 observations were used for the population PK analysis, to estimate the population PK parameters and the associated intersubject variability and residual error, to identify significant covariates, and to estimate their impact on exposure.</p>
<p>After visual inspection of the PK data following SC administration, plasma inotersen concentrations declined in a biphasic manner with time (<a href="#SD1" class="usa-link">Supplementary Fig. S1</a>). In addition, one, two, and three-compartment models were fit to the naive pooling of all available data, and the two-compartment model was confirmed as the most appropriate base model structure for inotersen population PK analysis. The model was parameterized for absorption rate constant (<em>K</em><sub>a</sub>), clearance (CL), central volume of distribution (<em>V</em><sub>c</sub>), intercompartmental clearance (<em>Q</em>), and peripheral volume of distribution (V<sub>p</sub>) (<a href="#f1" class="usa-link">Fig. 1</a>) and included interindividual variability (IIV) on CL, <em>V</em><sub>c</sub>, and <em>V</em><sub>p</sub>, with additive residual error model on log transformed data.</p>
<figure class="fig xbox font-sm" id="f1"><h4 class="obj_head">FIG. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=7249474_nat.2019.0822_figure1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3190/7249474/7a21f52db0ae/nat.2019.0822_figure1.jpg" loading="lazy" height="682" width="788" alt="FIG. 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/f1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Base PK and PK-PD model schematic. PK, pharmacokinetic; PD, pharmacodynamic.</p></figcaption></figure><p>The dose nonlinearity on clearance was observed in the Phase 1 data [<a href="#B5" class="usa-link" aria-describedby="B5">5</a>]. Thus, the dose nonlinearity was modeled by increasing the central clearance as the dose decreased using a simplified exponential model with dose administered being normalized to 300 mg dose.</p>
<p>Following the identification of the base model, population PK covariate relationships were systematically examined using the Gastonguay full model approach [<a href="#B8" class="usa-link" aria-describedby="B8">8</a>], with backward elimination of candidate covariates. The covariates assessed were body size [body weight, lean body mass (LBM), body surface area, and body mass index], age effects (&gt;65 years old), sex, race, baseline estimated glomerular filtration rate (eGFR), baseline albumin, baseline bilirubin normalized by upper limit of normal (ULN), baseline alanine aminotransferase (ALT), baseline TTR, TTR V30M mutation, disease state, frequently used concomitant medications (≥20% of population), including diuretics, antithrombotic, and non-NSAID analgesics, and region of the world from which the participants originated from.</p>
<p>ADAs were detected following chronic treatment with inotersen and were characterized by a late onset (median onset &gt;6 months) and low antibody titers (median peak titer ≤800) in the pivotal Phase 2/3 and OLE studies (internal data). The presence of ADA affected plasma trough concentrations of inotersen (<em>C</em><sub>trough</sub>) to various degrees; however, the presence of ADA did not change other PK parameters (including <em>C</em><sub>max</sub>, area under the curve [AUC], <em>t</em><sub>1/2λz</sub>, and CL<sub>ss</sub>/<em>F</em>). In addition, the presence of ADA did not have any effect on PD (serum TTR levels), clinical primary efficacy end points (mNIS +7 and Norfolk QoL-DN Score), nor incidence or seriousness of all safety measures evaluated. These findings suggest that anti-inotersen antibodies are binding antibodies but not neutralizing antibodies and did not affect pharmacological response, clinical benefit, or safety of inotersen. Because of these reasons, the PK data collected post the onset of ADA were excluded from the population PK model, in an effort to develop a population PK model and characterize potential effects of various covariates without confounding effects from ADA.</p>
<p>Candidate models were compared with state-of-the-art diagnostics, the selected final PK model was qualified with visual predictive checks, and the precision of the final model parameters was estimated using covariance and nonparametric bootstrap analyses.</p></section><section id="s010"><h3 class="pmc_sec_title">Population PD modeling</h3>
<p>The population PD model of inotersen was developed with the aim to understand the changes in TTR response following the administration of inotersen in patients with hATTR. Based on the mechanism of action of inotersen as described previously, the counter-clockwise hysteresis loop of the time-ordered TTR level versus inotersen plasma trough concentrations and visual inspection of the TTR over time data following SC administration (<a href="#SD2" class="usa-link">Supplementary Fig. S2</a>), an indirect response model with an inhibition function on the input rate was used as the base PD model to describe the effect of inotersen treatment on serum TTR levels:
</p>
<table class="disp-formula p" id="disp-formula1"><tr><td class="formula"><math id="M1" display="block"><mfrac><mrow><mi>d</mi><mi>T</mi><mi>T</mi><mi>R</mi></mrow><mrow><mi>d</mi><mi>t</mi></mrow></mfrac><mo class="MathClass-rel">=</mo><msub><mrow><mi>k</mi></mrow><mrow><mstyle mathvariant="normal"><mi>i</mi></mstyle><mi>n</mi></mrow></msub><mfenced separators="" open="(" close=")"><mrow><mn>1</mn><mo class="MathClass-bin">−</mo><mfrac><mrow><msub><mrow><mi>I</mi></mrow><mrow><mstyle mathvariant="normal"><mi>m</mi></mstyle><mi>a</mi><mi>x</mi></mrow></msub><msub><mrow><mi>C</mi></mrow><mrow><mstyle mathvariant="normal"><mi>p</mi></mstyle></mrow></msub></mrow><mrow><mi>I</mi><msub><mrow><mi>C</mi></mrow><mrow><mn>50</mn></mrow></msub><mstyle mathvariant="normal"></mstyle><mo class="MathClass-bin">+</mo><mstyle mathvariant="normal"></mstyle><msub><mrow><mi>C</mi></mrow><mrow><mstyle mathvariant="normal"><mi>p</mi></mstyle></mrow></msub></mrow></mfrac></mrow></mfenced><mo class="MathClass-bin">−</mo><msub><mrow><mi>k</mi></mrow><mrow><mstyle mathvariant="normal"><mi>o</mi></mstyle><mi>u</mi><mi>t</mi></mrow></msub><mi>T</mi><mi>T</mi><msub><mrow><mi>R</mi></mrow><mrow></mrow></msub></math></td></tr></table>
<p>Where <em>k</em><sub>in</sub> and <em>k</em><sub>out</sub> represent the zero-order synthesis rate and first order turnover of TTR, respectively. <em>I</em><sub>max</sub> and IC<sub>50</sub> describe the maximum inhibition of TTR and plasma concentration of inotersen corresponding to 50% of maximum drug effect, respectively.</p>
<p>The population PD model was developed following an iterative model building process using a nonlinear mixed effects approach. Modeling was performed on log-transformed TTR data, which were proved to be more stable and led to more consistent model convergence. Individual PK parameters obtained from the final population PK model were used to generate individual drug input for the PK/PD model. Covariates evaluated for the PD model included disease status (healthy volunteers vs. hATTR patients), baseline TTR levels, and TTR mutation (V30M and non-V30M). Final PD model was qualified with visual predictive checks, and the precision of the final model parameters was estimated using covariance and nonparametric bootstrap analyses.</p></section><section id="s011"><h3 class="pmc_sec_title">Simulations</h3>
<p>Simulations were conducted based on the final population PK and PD model to simulate concentration-time profiles of inotersen and TTR, as well as steady-state exposure PK parameters in patients with hATTR for the following dosing regimens:
</p>
<ul class="list" style="list-style-type:disc">
<li><p>300 mg QW for 65 weeks</p></li>
<li><p>300 mg once every other week (QOW) for 65 weeks</p></li>
<li><p>150 mg QW for 65 weeks</p></li>
<li><p>300 mg with loading dose on days 1, 3, and 5 during the first week, followed by QW for an additional 64 weeks</p></li>
</ul>
<p>A total of 500 replicated datasets were produced for each simulation, with parameter uncertainty included using the variance–covariance matrix from the final model as the prior distribution. In each replicated dataset, the 151 patients from the original dataset were used along with their demographic variables, thus total of 75,500 patients were simulated. Steady-state exposure measures (AUC<sub>0−τ</sub>, <em>C</em><sub>max</sub>, <em>C</em><sub>trough</sub>) from these simulations were summarized by geometric mean [90% confidence interval (CI)] following the first dose on day 1 and the last dose after 65 weeks of dosing. The predicted TTR levels from these simulations were plotted as median (90% prediction interval [PI]).</p></section></section><section id="s012"><h2 class="pmc_sec_title">Results</h2>
<section id="s013"><h3 class="pmc_sec_title">Population PK model</h3>
<p>Following the identification of the base model as a two-compartment linear model with first order absorption following SC administration and first order elimination from the central compartment, dose nonlinearity term was added, which resulted in a decrease in the objective function of 57.12 points, as well as a reduction of IIV in CL/<em>F</em>, <em>V</em><sub>c</sub>/<em>F</em>, and <em>V</em><sub>p</sub>/<em>F</em>. The final population PK model suggests that the apparent dose nonlinearity is driven by a higher plasma clearance (primarily distributional clearance) at the lowest dose level of 50 mg. This apparent nonlinearity, however, will not be clinically relevant because the projected clinical dose levels are in the range of 150–300 mg.</p>
<p>Then, a full covariate approach followed by stepwise backward elimination was undertaken, incorporating remaining predetermined covariates, and the full covariate model was then subject to backward elimination process to exclude statistically and clinically insignificant covariates. The effect of four different measures of body size (body weight, LBM, body surface area, and body mass index) on the clearance and central volume of distribution was evaluated individually. LBM was chosen as the measure of body size based on the largest drop in the OFV. The model included interindividual variability on clearance, central volume, and peripheral volume and with additive residual error model on log transformed data. As shown in <a href="#f2" class="usa-link">Figs. 2</a> and <a href="#f3" class="usa-link">3</a>, only LBM and disease state showed clinical significance and remained in the model, where LBM remained as covariate on the central and intercompartmental clearances and the central and peripheral volumes and disease status on the central compartment clearance and central volume.</p>
<figure class="fig xbox font-sm" id="f2"><h4 class="obj_head">FIG. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=7249474_nat.2019.0822_figure2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3190/7249474/a54ac16aa743/nat.2019.0822_figure2.jpg" loading="lazy" height="490" width="740" alt="FIG. 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/f2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Clinical significance testing for categorical covariates in full model: distribution of percentage change from reference individual. <em>Vertical red dashed lines</em>, boundaries representing the 20% clinical significant test; <em>closed circle</em>, median percentage change from the reference category; Whiskers, 5th and 95th CI of the percentage change from the reference category. Cl, apparent clearance, CL/F; Vc, apparent central volume, Vc/F; Amer for America, AA for African American.</p></figcaption></figure><figure class="fig xbox font-sm" id="f3"><h4 class="obj_head">FIG. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=7249474_nat.2019.0822_figure3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3190/7249474/0f14e9ff5980/nat.2019.0822_figure3.jpg" loading="lazy" height="490" width="740" alt="FIG. 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/f3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Clinical significance testing for continuous covariates in full model: distribution of 5th and 95th confidence intervals of percentage change from reference individual. <em>Y Axis Labels</em>, values of the 5<sup>th</sup> and the 95<sup>th</sup> percentile of the continuous covariate being tested are displayed as separate categories on the X-axis; <em>Vertical Red Dashed Lines</em>, boundaries representing the 20% cinicalsignificanfe test; Closed Circle, median percentage change from the reference category <em>Whisker</em>. 5<sup>th</sup> and 95<sup>th</sup> percentile of the percentage change from the reference category. B or Base refter to baseline. Cl, apparent clearance, CL/F and Apparent inter-compartmental clearence Q/F; Vc, apparent central volume, Vc/F; Vp, periphereal volumes Vp/F.</p></figcaption></figure><p>Bayesian <em>post hoc</em> estimates of exposures showed that the difference in the steady-state AUC<sub>τ</sub> or <em>C</em><sub>max</sub> was small between LBM quartile categories. For example, the geometric mean ratio for steady-state AUC<sub>τ</sub> and <em>C</em><sub>max</sub> was 1.38 and 1.34, respectively, between the first quartile (Q1) of LBM (LBM in the range of 31.1–45.7 kg) and the fourth quartile (Q4) (LBM in the range of 56.0–80.3 kg). The difference in geometric mean of <em>C</em><sub>trough</sub> level between Q1 and Q4 was even less, ∼10%. Similarly, small differences (&lt;30%) in the exposure are observed based on body weight quartile categories (Q1 in the range of 37.0–58.2 kg vs. Q4 in the range of 80.8–140 kg). Thus, overall the effect of body weight or LBM on inotersen exposure was considered to be small and may not be clinically relevant.</p>
<p>There were differences in some of the baseline clinical measures across disease groups, for example, hATTR patients had higher bilirubin levels and slightly lower baseline TTR levels; however, there was a larger range of baseline TTR levels in the hATTR population. The hATTR patients, as describe earlier, were in general an older population that had lower creatinine clearance levels compared to healthy volunteers. Given these correlations between disease status and other variables, disease status was selected preferentially as the covariate of interest if two covariates appeared to be correlated in the final model.</p>
<p>Other statistically and clinically insignificant covariates were excluded from the model through backward elimination process, which included age effects (&gt;65 years old), sex, race, baseline eGFR, baseline albumin, baseline bilirubin normalized by ULN, baseline ALT, baseline TTR, TTR V30M mutation, concomitant use of diuretics, antithrombotic, and non-NSAID analgesics, and region of the world. It was noted that the apparent differences in observations due to race should be interpreted with caution; as 87.6% of the subjects were Caucasians, these apparent differences could be the result of small sample size.</p>
<p>The final model was qualified using visual predictive checks and nonparametric bootstrap analysis. As indicated by the goodness-of-fit, residual diagnostic plots and prediction corrected visual predictive checks, the model provided an adequate characterization of the observed inotersen plasma concentration-time course (<a href="#SD3" class="usa-link">Supplementary Figs. S3</a> and <a href="#SD4" class="usa-link">S4</a>). The structural model parameters were generally estimated with good precision (% RSE &lt;30%), except for the covariate effect of disease status on CL/<em>F</em> and <em>V</em><sub>c</sub>/<em>F</em>. The final model parameter estimates are in good agreement with bootstrapping results and well within the 95% CIs of parameter estimates for each parameter (<a href="#tb2" class="usa-link">Table 2</a>). None of the random effects had shrinkage values &gt;30% or had the center of their distributions statistically different from zero.</p>
<section class="tw xbox font-sm" id="tb2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Parameter Estimates for Final Population Pharmacokinetic Model</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="left" valign="bottom" colspan="1" rowspan="1">Parameter</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Covariate model</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Estimate</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">% RSE</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">95% CI</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Clearance, CL (L/h)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.4</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">5.23</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.05–3.75</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Central volume, <em>V</em><sub>c</sub> (L)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.87</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">17.5–23.9</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Absorption rate constant, <em>K</em><sub>a</sub> (1/h)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.261</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.73</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.222–0.301</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Peripheral volume, <em>V</em><sub>p</sub> (L)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">230</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">13.8</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">167–292</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Intercompartmental clearance, <em>Q</em> (L/h)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.266</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">9.61</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.216–0.315</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Dose effect ∼ CL</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Exponential</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.97</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">25.2</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">2.01–5.93</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Lean body mass ∼ CL/<em>Q</em>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Power-centered on median</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1 FIXED</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Lean body mass ∼ <em>V</em><sub>c</sub>/<em>V</em><sub>p</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Power-centered on median</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1 FIXED</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Disease ∼ CL</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Proportional</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.111</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">46.9</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.009–0.214</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Disease ∼ <em>V</em><sub>c</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Proportional</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−0.284</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">31.4</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−0.459 to −0.109</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Covariance, <em>V</em><sub>c</sub> ∼ CL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.049</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">48.4</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.003–0.096</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Covariance, CL ∼ <em>V</em><sub>p</sub>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−0.145</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">27.1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−0.222 to −0.068</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup><em>V</em><sub>c</sub>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.335</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">27</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.158–0.512</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup> CL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.071</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">21.3</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.041–0.101</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup><em>V</em><sub>p</sub>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.677</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">21</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.399–0.955</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Residual variability, σ<sup>2</sup>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Log additive error</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.168</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">5.29</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.151–0.186</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tb2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tf3"><p>Base model did not have any covariates; reduced and final models had covariates removed as result of analysis. Covariances of parameter displayed as “ω<sup>2</sup> parameter.”</p></div>
<div class="fn" id="tf4"><p>% RSE, relative standard error (%) calculated as standard error divided by parameter estimate; CI, confidence interval; NA, not applicable; AUC, area under the curve.</p></div>
</div></section><p>Based on final estimated population PK parameters, the calculated alpha and beta (terminal) half-lives are 3.91 hs and 26.9 days, respectively, consistent with the PK property of inotersen being biphasic profile with an initial rapid disposition phase followed by a slower elimination phase with apparent terminal elimination half-life of ∼4 weeks. The calculated accumulation ratio based on beta and dosing interval is 6.07, in agreement with the simulation results (<a href="#tb4" class="usa-link">Table 4</a>).</p>
<section class="tw xbox font-sm" id="tb4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Simulated Measures of Exposure for Additional Dosing Regimens</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="left" valign="bottom" colspan="1" rowspan="1">Regimen</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Day/type</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">AUC<sub>0–τ</sub> (μg · h/mL)</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">C<sub>max</sub> (μg/mL)</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">C<sub>trough</sub> (ng/mL)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">84.4 (77.6–91.6)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.35 (5.61–7.17)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">5.62 (4.92–6.24)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QOW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">85.5 (78.4–92.5)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.33 (5.66–7.18)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">4.28 (3.82–4.74)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Loading + 300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">85.5 (78.5–92.8)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.36 (5.76–7.26)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">25.7<sup><a href="#tf8" class="usa-link">a</a></sup> (20.9–31.8)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">150 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">42.3 (38.8–45.9)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.16 (2.81–3.57)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">2.81 (2.45–3.11)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">449</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">89.9 (82.4–97.4)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.39 (5.65–7.20)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">34.3 (31.0–38.2)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QOW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">449</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">90.1 (82.6–97.5)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.34 (5.67–7.20)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">14.8 (13.3–16.8)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Loading + 300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">449</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">90.0 (82.8–97.8)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.34 (5.72–7.24)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">34.3 (30.6–38.3)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">150 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">449</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">45.0 (41.4–48.8)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.18 (2.83–3.59)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">17.2 (15.5–19.1)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">AR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.06 (1.06–1.07)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.01 (1.00–1.01)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.11 (5.26–7.30)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">300 mg QOW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">AR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.05 (1.05–1.06)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.00 (1.00–1.00)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">3.45 (2.99–4.08)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Loading + 300 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">AR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.05 (1.05–1.06)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.996 (0.991–0.999)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">150 mg QW</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">AR</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.06 (1.06–1.07)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.01 (1.00–1.01)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.14 (5.27–7.26)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tb4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tf7"><p>Data presented are geometric mean (90% CI).</p></div>
<div class="fn" id="tf8">
<sup><sup>a</sup></sup><p class="display-inline"><em>C</em><sub>trough</sub> after the dose on day 1 is 48 h time point during loading dose period.</p>
</div>
<div class="fn" id="tf9"><p>AUC, area under cureve; QW, once weekly; QOW, once every other week; AR, accumulation ratio.</p></div>
</div></section></section><section id="s014"><h3 class="pmc_sec_title">Population PD modeling</h3>
<p>As described earlier, there was a slight difference in baseline TTR levels between healthy volunteers and hATTR patients; therefore, disease effect on baseline was added as a covariate to the estimated baseline. V30M mutation showed no effect on the estimated IC<sub>50</sub> value for hATTR patients.</p>
<p>The robustness and precision of the final model parameter estimates were confirmed by the 95% CIs from the bootstrap results (<a href="#tb3" class="usa-link">Table 3</a>). The overall population <em>I</em><sub>max</sub> and IC<sub>50</sub>, together with 95% CI, was estimated to be 0.913 (0.899–0.925) and 9.07 (8.08–10.1) ng/mL, respectively. The final model was qualified using visual predictive checks and nonparametric bootstrap analysis. As indicated by the goodness-of-fit, residual diagnostic plots and prediction corrected visual predictive check plots (1,000 simulations), the model provided an adequate characterization of the observed TTR concentration–time course (<a href="#SD5" class="usa-link">Supplementary Figs. S5</a> and <a href="#SD6" class="usa-link">S6</a>). The 5th, 50th, and 95th percentiles of the simulations were consistent with the observed data. In addition, the observed data (blue circles) were well within 90% of the prediction interval. Although the prediction variability was larger than the observed data, the predicted median values were mainly used when comparing various simulated dosing regimens. Therefore, these support the adequacy of the model and its suitability to investigate alternative dosing regimens using simulation.</p>
<section class="tw xbox font-sm" id="tb3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Final Population Pharmacokinetic/Pharmacodynamic Model Parameter Estimates</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="left" valign="bottom" colspan="1" rowspan="1">Parameter</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Units</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Final model estimates</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">95% CI</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">
<em>I</em><sub>max</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.913</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.899–0.925)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">IC<sub>50</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">ng/mL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">9.07</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(8.08–10.1)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Estimated baseline</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">mg/dL</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.4</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(19.7–21.1)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">∼Disease effect on baseline (healthy volunteers)</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.269</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.178–0.360)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">
<em>k</em><sub>out</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">h<sup>−1</sup>
</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.00308</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.00289–0.00327)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup> IC50</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.953</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.702 − 1.20)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Covariance, IC50 ∼ <em>k</em><sub>out</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−0.182</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(−0.297 to −0.0669)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup><em>k</em><sub>out</sub>
</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.288</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.187 − 0.389)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">ω<sup>2</sup> Baseline</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.0537</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.0404 − 0.0670)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Residual variability (log space), (SD)</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Proportional error</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">0.13</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(0.117 − 0.143)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Additive error</td>
<td align="left" valign="bottom" colspan="1" rowspan="1"> </td>
<td align="center" valign="bottom" colspan="1" rowspan="1">1.35</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">(1.26 − 1.45)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tb3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tf5"><p>Disease effect covariate was the proportional shift in baseline TTR levels of healthy volunteers compared to hATTR patients. The 95% CI was determined from the successful covariance step of the PD model.</p></div>
<div class="fn" id="tf6"><p>PD, pharmacodynamic; hATTR, hereditary transthyretin amyloidosis.</p></div>
</div></section></section><section id="s015"><h3 class="pmc_sec_title">Simulations</h3>
<p>The final population PK and PD model was used to simulate four different dosing regimens of inotersen, from which the geometric mean along with 90% CI was calculated for AUC<sub>0−τ</sub>, <em>C</em><sub>max</sub>, and <em>C</em><sub>trough</sub> for day 1 and steady state (<a href="#tb4" class="usa-link">Table 4</a>). Plots of the median plasma trough concentration and TTR profiles over time along with 90% prediction interval were created for each dosing regimen (<a href="#f4" class="usa-link">Figs. 4</a> and <a href="#f5" class="usa-link">5</a>). PK simulations showed that there was little accumulation in AUC<sub>0−τ</sub> and <em>C</em><sub>max</sub> for all dosing regimens. There was also little difference in AUC<sub>0−τ</sub> between the different 300-mg regimens, while the 150-mg regimen produced AUC<sub>0−τ</sub> approximately half of the 300-mg regimens. A similar trend was seen with <em>C</em><sub>max</sub>.</p>
<figure class="fig xbox font-sm" id="f4"><h4 class="obj_head">FIG. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=7249474_nat.2019.0822_figure4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3190/7249474/2a3316716b31/nat.2019.0822_figure4.jpg" loading="lazy" height="508" width="740" alt="FIG. 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/f4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Simulated plasma trough concentration profile for ISIS 420915 for various dosing regimens.</p></figcaption></figure><figure class="fig xbox font-sm" id="f5"><h4 class="obj_head">FIG. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=7249474_nat.2019.0822_figure5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3190/7249474/a4f49b05653a/nat.2019.0822_figure5.jpg" loading="lazy" height="494" width="740" alt="FIG. 5."></a></p>
<div class="p text-right font-secondary"><a href="figure/f5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Predicted transthyretin levels for various simulated dosing regimens. <em>Solid lines</em> represent medians, and <em>shaded regions</em> represent 90% PI.</p></figcaption></figure><p>The use of 300 mg loading doses achieved trough levels of ∼65.1% and 85.6% of the steady-state level after 1 and 3 months of 300 mg QW treatment, compared with 47.4% and 81.5%, respectively, without the use of loading doses. At steady state, the <em>C</em><sub>trough</sub> levels following 300 mg QOW and 150 mg QW treatment regimen were 14.8 (13.3–16.8) ng/mL and 17.2 (15.5–19.1) ng/mL, respectively, approximately one half of the <em>C</em><sub>trough</sub> level [34.4 (31.0–38.2) ng/mL] following 300 mg QW treatment regimen. Loading-dose regimen did not alter steady-state trough levels, but reduced time to reach approximately two-thirds of the steady-state <em>C</em><sub>trough</sub> (∼23 ng/mL) level from 2 months to 1 month (<a href="#f4" class="usa-link">Fig. 4</a>).</p>
<p>Similarly, the use of 300 mg loading doses followed by 300 mg QW achieved mean percent change from baseline TTR levels of approximately −45.1%, −57.5%, and −69.0% at 2 weeks, 1 month, and 3 months, respectively, compared to approximately −34.8%, −51.2%, and −67.9% with no loading doses (<a href="#f5" class="usa-link">Fig. 5</a>; <a href="#tb5" class="usa-link">Table 5</a>). A dosing regimen of 150 mg QW resulted in mean percent change from baseline TTR levels of approximately −28.1%, −42.6%, and −58.6% at 2 weeks, 1 month, and 3 months, respectively. For 300 mg QOW, the values were −24.7%, −38.0%, and −53.8%, respectively. Overall, 300 mg loading doses followed by 300 mg QW would result in a slightly faster onset of TTR reduction than without loading doses, and the same predicted geometric mean reduction of approximately −71.9% at steady state.</p>
<section class="tw xbox font-sm" id="tb5"><h4 class="obj_head">Table 5.</h4>
<div class="caption p"><p>Simulated Transthyretin Levels Over Time for Various Dosing Regimens</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="left" valign="bottom" colspan="1" rowspan="1">Dose</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">Day</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">TTR level (mg/dL)</th>
<th align="center" valign="bottom" colspan="1" rowspan="1">TTR % change from baseline (%)</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="6" align="left" valign="bottom" colspan="1">300 mg QW</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Baseline</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.4 (19.7–21.2)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">15.7 (15.0–16.4)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−20.2 (−23.0 to −17.5)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 14</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">12.4 (11.8–13.1)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−34.8 (−37.9 to −32.0)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 28</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">8.91 (8.33–9.53)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−51.2 (−54.1 to −48.4)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 85</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">5.56 (5.12–6.02)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−67.9 (−70.2 to −65.5)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day (steady state)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">4.82 (4.41–5.22)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−71.9 (−74.0 to −69.7)</td>
</tr>
<tr>
<td rowspan="6" align="left" valign="bottom" colspan="1">300 mg QW with loading dose</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Baseline</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.4 (19.7–21.1)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">13.0 (12.4–13.7)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−32.5 (−35.3 to −29.2)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 14</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">10.3 (9.72–11.0)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−45.1 (−47.8 to −42.3)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 28</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.67 (7.10–8.26)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−57.5 (−60.4 to −54.8)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 85</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.39 (6.84–7.96)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−69.0 (−71.1 to −66.8)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day (steady state)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">4.78 (4.39–5.22)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−71.9 (−74.1 to −69.8)</td>
</tr>
<tr>
<td rowspan="6" align="left" valign="bottom" colspan="1">300 mg Q2W</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Baseline</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.4 (19.7–21.2)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">15.7 (15.0–16.4)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−20.2 (−23.0 to −17.5)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 14</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">14.6 (13.9–15.3)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−24.7 (−27.8 to −21.8)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 28</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">11.7 (11.0–12.6)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−38.0 (−41.1 to −35.0)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 85</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">8.29 (7.70–8.92)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−53.8 (−56.7 to −50.9)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day (steady state)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.24 (6.67–7.82)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−58.8 (−61.5 to −56.1)</td>
</tr>
<tr>
<td rowspan="6" align="left" valign="bottom" colspan="1">150 mg QW</td>
<td align="left" valign="bottom" colspan="1" rowspan="1">Baseline</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">20.4 (19.7–21.2)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 7</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">16.6 (15.9–17.4)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−15.9 (−18.6 to −13.3)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 14</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">13.9 (13.3–14.6)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−28.1 (−31.5 to −25.3)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 28</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">10.8 (10.1–11.4)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−42.6 (−45.6 to −39.6)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day 85</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">7.39 (6.84–7.96)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−58.6 (−61.2 to −56.0)</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="1" rowspan="1">Day (steady state)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">6.47 (5.95–6.98)</td>
<td align="center" valign="bottom" colspan="1" rowspan="1">−63.1 (−65.7 to −60.5)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tb5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section></section><section id="s016"><h2 class="pmc_sec_title">Discussion</h2>
<p>We have developed and reported the first population PK and PK/PD model for an ASO therapeutic, inotersen. Inotersen PK is well described by a two-compartment linear PK model, and its pharmacological effect on TTR is well described using an inhibitory effect indirect response PD model, where TTR formation is modulated by inotersen exposure.</p>
<p>Out of the demographic parameters evaluated, including age, gender, body weight, and race, only body weight or body size was shown to be a significant covariate on inotersen clearance and volume of distribution. However, its overall impact on PK exposure (<em>C</em><sub>max</sub>, AUC, or <em>C</em><sub>trough</sub>) appeared to be small (&lt;30%) by body weight and 38% by LBM. Nonetheless, the clinical relevance of body weight on plasma exposure, selected safety (platelet), and PD (TTR reduction) measures was further evaluated by graphical analysis. Results showed a weak association between platelet reduction and inotersen plasma exposures (<em>C</em><sub>max</sub> and AUC), but less with <em>C</em><sub>trough</sub> (<a href="#SD7" class="usa-link">Supplementary Fig. S7</a>) among patients at the same dose level. Similarly, a weak association was observed between body weight and platelet reduction, but not with TTR reduction (internal data). These results suggest that dose reduction, if warranted, would be helpful in reducing the risk of platelet reduction without comprising the PD activity.</p>
<p>The clearance and central volume of inotersen were not affected by baseline TTR level or TTR mutation. However, disease status was retained as a covariate on central compartment clearance and central volume. Nonetheless, the contribution of the disease status on PK was small. For example, the population typical value for central clearance (CL/<em>F</em>) was 3.40 and 3.18 L/h in patients with hATTR-PN, based on <em>post hoc</em> analysis, while the apparent volume of distribution (<em>V</em><sub>ss</sub>/<em>F</em>) was estimated to be 250.7 L as the typical value and 293 L in patients with hATTR.</p>
<p>Even though the PK of inotersen is not affected by hepatic function, no conclusions can be drawn for patients with hepatic impairment due to the absence of such population in the clinical program. The population PK analysis showed that renal function, as represented by baseline eGFR, is not a statistically significant covariate for inotersen clearance, in the range of 41.3–127 mL/min/1.73 m<sup>2</sup>. Thus, no dose adjustment is necessary in patients with mild-to-moderate renal impairment. Given the lack of experience in patients with low moderate and severe renal impairment for inotersen, no conclusions on the safety in such populations can be drawn, even though the PK of inotersen is expected to be similar across a range renal function impairment based on almost exclusive clearance of inotersen through ubiquitous nucleases in tissues.</p>
<p>Commonly used concomitant medications in the Phase 2/3 study included diuretics (30.5%), antithrombotic (36.4%), and non-NSAID analgesics (83.4%) in patients with hATTR. None of these concomitant medications showed any clinically significant effect on clearance of inotersen and was not included in the final population PK model. Therefore, dose adjustment for inotersen in consideration of PK interaction when used concomitantly with these agents is not necessary, consistent with different metabolism pathways for inotersen (ubiquitous nuclease mediated metabolism) and small molecule drugs (mainly metabolized by cytochromes P450 [CYPs]).</p>
<p>There was a slight difference between TTR baseline levels for healthy volunteers and patients with hATTR; therefore, disease effect on TTR baseline was added as a covariate to the estimated baseline in the population PK/PD model. There was little difference in the estimated IC<sub>50</sub> for patients with (8.17 ng/mL) and without (9.19 ng/mL) V30M mutation. The model determined <em>k</em><sub>out</sub> was 0.00308/h, corresponding to a half-life of ∼9 days, which is much longer than the ∼2-day half-life of plasma TTR (aka, prealbumin) as reported in the literature (turnover rate of 0.296/day) [<a href="#B9" class="usa-link" aria-describedby="B9">9</a>]. This discrepancy may be explained by the PD profiles being driven by inotersen PK, which is the rate-limiting step.</p>
<p>The change from baseline for mNIS +7 score on week 66 (day 449)plotted against day 85 TTR levels showed clear distinction between placebo and inotersen groups, and the majority of patients on inotersen had &gt;50% reduction in TTR levels (<a href="#SD8" class="usa-link">Supplementary Fig. S8a</a>). Similarly, the change from baseline for Norfolk QoL-DN score on week 66 plotted against day 85 TTR levels showed similar results as noted for mNIS +7 (<a href="#SD8" class="usa-link">Supplementary Fig. S8b</a>). These results suggest that a TTR reduction of approximately &gt;50% is associated with clinical benefit.</p>
<p>TTR reduction is dose- and exposure dependent. PK/PD simulations showed that 300 mg weekly dosing would produce the best numeric TTR reduction; however, the range of TTR reduction is largely overlapping among the three dosing regimens simulated, that is, 300 mg weekly, 300 mg biweekly, and 150 mg weekly, suggesting that the two lower doses would be effective in TTR reduction for the majority of patients. Loading dose shortened the time to steady state, but showed little effect on TTR reduction at 3 months and beyond. Therefore, loading dose may not be necessary for chronic treatment with inotersen.</p>
<p>In summary, the population PK and PK/PD models developed in this study may be useful for dose optimization in patients receiving inotersen and for development of an inotersen follow-on in the same patient population.</p></section><section id="sec17"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="SD1"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2109"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig1.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig1.pdf</a><sup> (118.2KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD2"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2114"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig2.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig2.pdf</a><sup> (140.4KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD3"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2119"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig3.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig3.pdf</a><sup> (228KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD4"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2124"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig4.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig4.pdf</a><sup> (183.4KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD5"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2129"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig5.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig5.pdf</a><sup> (239.3KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD6"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2134"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig6.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig6.pdf</a><sup> (209.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD7"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2139"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig7.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig7.pdf</a><sup> (189.7KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="SD8"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p" id="d38e2144"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig8.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig8.pdf</a><sup> (153.6KB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors thank Drs. Hoke for his scientific discussion, Angela Colabucci and Robert Saunders for their administrative support.</p></section><section id="s017"><h2 class="pmc_sec_title">Author Disclosure Statement</h2>
<p>R.Z.Y., S.H., R.G., B.M., S.H., and Y.W. are employees of Ionis Pharmaceuticals, Inc. and hold stock in the company. E.J.A. is an employee of Avidity Biosciences, San Diego, CA and was a former employee of Ionis Pharmaceuticals and holds stock in the company. J.W.C. is currently an employee of GlaxoSmithKline and was employed with Parexel at the time of work.</p></section><section id="s018"><h2 class="pmc_sec_title">Funding Information</h2>
<p>Ionis Pharmaceuticals, Inc. supported this work.</p></section><section id="s019"><h2 class="pmc_sec_title">Supplementary Material</h2>
<p><a href="#SD1" class="usa-link">Supplementary Figure S1</a></p>
<p><a href="#SD2" class="usa-link">Supplementary Figure S2</a></p>
<p><a href="#SD3" class="usa-link">Supplementary Figure S3</a></p>
<p><a href="#SD4" class="usa-link">Supplementary Figure S4</a></p>
<p><a href="#SD5" class="usa-link">Supplementary Figure S5</a></p>
<p><a href="#SD6" class="usa-link">Supplementary Figure S6</a></p>
<p><a href="#SD7" class="usa-link">Supplementary Figure S7</a></p>
<p><a href="#SD8" class="usa-link">Supplementary Figure S8</a></p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1">
<span class="label">1.</span><cite>
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, et al.  (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med
379:22–31</cite> [<a href="https://doi.org/10.1056/NEJMoa1716793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inotersen%20treatment%20for%20patients%20with%20hereditary%20transthyretin%20amyloidosis&amp;author=MD%20Benson&amp;author=M%20Waddington-Cruz&amp;author=JL%20Berk&amp;author=M%20Polydefkis&amp;author=PJ%20Dyck&amp;volume=379&amp;publication_year=2018&amp;pages=22-31&amp;pmid=29972757&amp;doi=10.1056/NEJMoa1716793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2">
<span class="label">2.</span><cite>
Quintas A, Vaz DC, Cardoso I, Saraiva MJ and Brito RM (2001). Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem
276:27207–27213</cite> [<a href="https://doi.org/10.1074/jbc.M101024200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11306576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=Tetramer%20dissociation%20and%20monomer%20partial%20unfolding%20precedes%20protofibril%20formation%20in%20amyloidogenic%20transthyretin%20variants&amp;author=A%20Quintas&amp;author=DC%20Vaz&amp;author=I%20Cardoso&amp;author=MJ%20Saraiva&amp;author=RM%20Brito&amp;volume=276&amp;publication_year=2001&amp;pages=27207-27213&amp;pmid=11306576&amp;doi=10.1074/jbc.M101024200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3">
<span class="label">3.</span><cite>
Plante-Bordeneuve V and Said G (2011). Familial amyloid polyneuropathy. Lancet Neurol
10:1086–1097</cite> [<a href="https://doi.org/10.1016/S1474-4422(11)70246-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22094129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Familial%20amyloid%20polyneuropathy&amp;author=V%20Plante-Bordeneuve&amp;author=G%20Said&amp;volume=10&amp;publication_year=2011&amp;pages=1086-1097&amp;pmid=22094129&amp;doi=10.1016/S1474-4422(11)70246-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4">
<span class="label">4.</span><cite>
Coelho T, Ericzon BG, Falk R, Grogan DR, Ikeda S, Maurer M, Planté-Bordeneuve V, Suhr O and Trigo P (2008). A Physician's Guide to Transthyretin Amyloidosis. Clarkston, MI: Amyloidosis Foundation. pp 1–16</cite> [<a href="https://scholar.google.com/scholar_lookup?title=A%20Physician's%20Guide%20to%20Transthyretin%20Amyloidosis&amp;author=T%20Coelho&amp;author=BG%20Ericzon&amp;author=R%20Falk&amp;author=DR%20Grogan&amp;author=S%20Ikeda&amp;publication_year=2008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5">
<span class="label">5.</span><cite>
Liefaard L, Grundy J, Williams N, Shenker A, and C Chen (2013). Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects. Population Approach Group Europe (PAGE) Meeting: Abstract III-15, pp 228
<a href="https://www.page-meeting.org/page/page2013/PAGE2013ProgramAndAbstracts130604.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.page-meeting.org/page/page2013/PAGE2013ProgramAndAbstracts130604.pdf</a></cite> [<a href="https://scholar.google.com/scholar_lookup?Liefaard%20L,%20Grundy%20J,%20Williams%20N,%20Shenker%20A,%20and%20C%20Chen%20(2013).%20Predicting%20levels%20of%20pharmacological%20response%20in%20long-term%20patient%20trials%20based%20on%20short-term%20dosing%20PK%20and%20biomarker%20data%20from%20healthy%20subjects.%20Population%20Approach%20Group%20Europe%20(PAGE)%20Meeting:%20Abstract%20III-15,%20pp%20228%20https://www.page-meeting.org/page/page2013/PAGE2013ProgramAndAbstracts130604.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6">
<span class="label">6.</span><cite>
Ionis-Pharmaceuticals. (2018). Full prescribing information for Tegsedi, <a href="https://accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf</a> accessed January17, 2020</cite>
</li>
<li id="B7">
<span class="label">7.</span><cite>
Yu RZ, Baker B, Chappel A, Geary RS, Chueng E and Levin AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem
304:19–25</cite> [<a href="https://doi.org/10.1006/abio.2002.5576" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11969184/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anal%20Biochem&amp;title=Development%20of%20an%20ultrasensitive%20noncompetitive%20hybridization-ligation%20enzyme-linked%20immunosorbent%20assay%20for%20the%20determination%20of%20phosphorothioate%20oligodeoxynucleotide%20in%20plasma&amp;author=RZ%20Yu&amp;author=B%20Baker&amp;author=A%20Chappel&amp;author=RS%20Geary&amp;author=E%20Chueng&amp;volume=304&amp;publication_year=2002&amp;pages=19-25&amp;pmid=11969184&amp;doi=10.1006/abio.2002.5576&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8">
<span class="label">8.</span><cite>
Gastonguay M. (2011). Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. Abstract
2229, p 20
<a href="http://www.page-meeting.org/?abstract=2229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.page-meeting.org/?abstract=2229</a></cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Abstract&amp;title=Full%20covariate%20models%20as%20an%20alternative%20to%20methods%20relying%20on%20statistical%20significance%20for%20inferences%20about%20covariate%20effects:%20a%20review%20of%20methodology%20and%2042%20case%20studies&amp;author=M%20Gastonguay&amp;volume=2229&amp;publication_year=2011&amp;pages=20&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9">
<span class="label">9.</span><cite>
Socolow EL, Woeber KA, Purdy RH, Holloway MT and Ingbar SH (1965). Preparation of I-131-labeled human serum prealbumin and its metabolism in normal and sick patients. J Clin Invest
44:1600–1609</cite> [<a href="https://doi.org/10.1172/JCI105266" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC292644/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/5840530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&amp;title=Preparation%20of%20I-131-labeled%20human%20serum%20prealbumin%20and%20its%20metabolism%20in%20normal%20and%20sick%20patients&amp;author=EL%20Socolow&amp;author=KA%20Woeber&amp;author=RH%20Purdy&amp;author=MT%20Holloway&amp;author=SH%20Ingbar&amp;volume=44&amp;publication_year=1965&amp;pages=1600-1609&amp;pmid=5840530&amp;doi=10.1172/JCI105266&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig1.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig1.pdf</a><sup> (118.2KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig2.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig2.pdf</a><sup> (140.4KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig3.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig3.pdf</a><sup> (228KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig4.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig4.pdf</a><sup> (183.4KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig5.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig5.pdf</a><sup> (239.3KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig6.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig6.pdf</a><sup> (209.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material7_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig7.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig7.pdf</a><sup> (189.7KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material8_reqid_"><div class="caption p"><span>Supplemental data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/7249474/bin/Supp_Fig8.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp_Fig8.pdf</a><sup> (153.6KB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Nucleic Acid Therapeutics are provided here courtesy of <strong>Mary Ann Liebert, Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1089/nat.2019.0822"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/nat.2019.0822.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (661.9 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/7249474/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/7249474/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC7249474%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC7249474/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC7249474/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC7249474/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/32286934/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC7249474/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/32286934/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC7249474/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/7249474/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="z6pdJmlAWlkE6BMljWHDtVXm4dFXMfMUAPcUc7JMTHzaq45GxaMjhzpWP1VxpPty">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
